€289.63
0.63% yesterday
L&S, Jul 01, 10:55 pm CET
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Amgen Share price

$311.01
+3.59 1.17% 1M
+22.99 7.98% 6M
+22.99 7.98% YTD
+86.00 38.22% 1Y
+64.11 25.97% 3Y
+124.66 66.90% 5Y
+190.70 158.51% 10Y
NYSE, Closing price Mon, Jul 01 2024
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Key figures

Market capitalization $166.84b
Enterprise Value $221.15b
PER (TTM) P/E ratio 44.47
EV/FCF (TTM) EV/FCF 31.16
EV/Sales (TTM) EV/Sales 7.53
P/S ratio (TTM) P/S ratio 5.68
P/B ratio (TTM) P/B ratio 33.22
Dividend yield 2.74%
Last dividend (FY23) $8.52
Sales growth (TTM) Sales growth 13.18%
Turnover (TTM) Turnover $29.35b
EBIT (operating result TTM) EBIT $7.29b
Free cash flow (TTM) Free cash flow $7.10b
Cash position $9.71b
EPS (TTM) EPS $6.99
P/E ratio expected 36.12
P/S ratio expected 5.06
EV/Sales expected 6.70
Short interest 1.70%
Show more

Register now for free to activate an alarm for the Amgen share.

Activate alerts on the share price, dividend yield, valuation (e.g. P/E ratio or EV/sales) or strategy scores and sit back and relax.

Amgen Share analysis

Analyst opinions

29 Analysts have issued a Amgen forecast:

14x Buy
48%
13x Hold
45%
2x Sell
7%

Analyst opinions

29 Analysts have issued a Amgen forecast:

Buy
48%
Hold
45%
Sell
7%

Financial data from Amgen

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
29,353 29,353
13% 13%
100%
- Direct costs 9,931 9,931
51% 51%
34%
19,422 19,422
0% 0%
66%
- Selling and administrative expenses 2,505 2,505
4% 4%
9%
- Research and development costs 5,057 5,057
12% 12%
17%
11,860 11,860
3% 3%
40%
- Depreciation and amortization 4,570 4,570
30% 30%
16%
EBIT (operating result) EBIT 7,290 7,290
17% 17%
25%
Net profit 3,763 3,763
52% 52%
13%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Amgen share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Amgen Share News

Positive
The Motley Fool
3 days ago
Amgen has maintained an impressive dividend streak over the past decade. The company's business should allow it to maintain this momentum for a while.
Positive
24/7 Wall Street
5 days ago
24/7 Wall St. Insights Jefferies is one of Wall Street's fastest-growing firms.
Positive
The Motley Fool
5 days ago
Amgen has been one of the best performing stocks since its IPO in 1983. Over the prior 12 months, the biotech's shares have continued this rich tradition.
More Amgen News

Company profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 26,700
Founded 1980
Website www.amgen.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now